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Abstract
Background: The aim of this study was to identify BRCA1 and BRCA2 mutations in the Estonian population. We 
analyzed genetic data and questionnaire from 64 early-onset (< 45 y) breast cancer patients, 47 familial cases (patients 
with breast or ovarian cancer and a case of these cancers in the family), and 33 predictive cases (patients without breast 
or ovarian cancer, with a family history of such diseases) from Estonia for mutations in the BRCA1 gene. A sub-set of 
familial cases and predictive cases were also analyzed for mutations in the BRCA2 gene.
Methods: For mutation detection, we used the Polymerase Chain Reaction-Single Stranded Conformation 
Polymorphism Heteroduplex Analysis (PCR-SSCP-HD), followed by direct DNA sequencing.
Results: We identified three clinically important mutations in the BRCA1 gene, including seven occurrences of the 
c.5382insC mutation, three of c.4154delA, and one instance of c.3881_3882delGA. We also detected six 
polymorphisms: c.2430T>C, c.3232A>G, c.4158A>G, c.4427T>C, c.4956A>G, and c.5002T>C. Four sequence alterations 
were detected in introns: c.560+64delT, c.560+ [36-38delCTT, 52-63del12], c.666-58delT, and 
c.5396+60insGTATTCCACTCC. In the BRCA2 gene, two clinically important mutations were found: c.9610C>T and 
c.6631delTTAAATG. Additionally, two alterations (c.7049G>T and c.7069+80delTTAG) with unknown clinical 
significance were detected.
Conclusions: In our dataset, the overall frequency of clinically important BRCA1 mutations in early-onset patients, 
familial cases, and predictive testing was 7.6% (144 cases, 11 mutation carriers). Pathogenic mutations were identified 
in 4 of the 64 early-onset breast cancer cases (6.3%). In familial cases, clinically important mutations in the BRCA1 gene 
were found in 6 of the 47 individuals analyzed (12.8%). In predictive cases, 1 clinically important mutation was detected 
in 33 individuals studied (3%). The occurrence of clinically important mutations in BRCA2 in familial cases of breast 
cancer was 2 of the 16 individuals analyzed (12.5%).
Background
Breast cancer is the most common cancer in Estonian
women between the ages of 30 and 74. Since 1978, the
Estonian Cancer Registry has been collecting data
regarding all cancer diagnoses in the country (population
1,370,052 in 2000). In the year 2000, 538 new cases of
breast cancer were diagnosed, 65 of which occurred in
women younger than 45. For all breast cancer cases, the
crude incidence is 72.9 per 100,000 for Estonia [1]. Since
the initial study localizing the breast cancer gene BRCA1
to chromosome 17q21 [2] and the isolation of the BRCA1
gene (OMIM#113705) [3], many mutation detection
studies have been undertaken. The Breast Cancer Infor-
mation Core (BIC) website http://research.nhgri.nih.gov/
projects/bic/ and Cancer Genetics Web for BRCA1
describes more than 1500 mutations in the BRCA1 gene
alone. The lifetime risk of breast cancer for Caucasian
BRCA1 mutation carriers is 60-85%, while the lifetime
risk of ovarian cancer is 15-40% [4]. The breast cancer
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susceptibility gene BRCA2 (OMIM#600185) [5] is also
related to an increased risk of ovarian cancer [6].
The aim of the present study was to identify BRCA1
and BRCA2 mutations that could be used in diagnostics
to provide the appropriate genetic counseling and treat-
ment for patients in Estonia. We analyzed genetic data
and questionnaire from individuals who had a family his-
tory of breast or ovarian cancer, as this is the major risk
factor for familial breast cancer. In addition, developing
breast cancer at a young age could indicate a genetic pre-
disposition to the disease, particularly a mutation in the
BRCA1 gene. Therefore, we also analyzed patients with
an onset of breast cancer before the age of 45, regardless
of family history. Because mutations may be localized
throughout the BRCA1 and BRCA2 genes, the entire
genes were analyzed in order to detect mutations in
familial cases. Additionally, we analyzed the entire
BRCA1 gene in early-onset cases. We used the Single
Stranded Conformation Polymorphism Hederoduplex
Analysis (SSCP-HD) method, followed by direct Sanger
dideoxy DNA sequencing. The entire coding regions and
exon-intron junctions in the BRCA1 and BRCA2 genes
were sequenced in samples which presented abnormal
electrophoresis patterns in SSCP-HD.
Methods
Patients
We screened for BRCA1 mutations in three groups of
patients: early-onset, familial, and predictive cases, and
also searched for BRCA2 mutations in all predictive and
in some familial cases. The three patient groups are
defined as the following:
1. Early-onset cases were identified as patients who had
been diagnosed with breast cancer before age 45. We
included patients who had been diagnosed during the five
years prior to the start date of the study (Apr. 10, 2000),
and also included new cases diagnosed after that date.
Patient blood samples were collected between Apr. 10,
2000 and Feb. 10, 2003. A total of 95 patients were origi-
nally included in this group. Patients were asked to fill out
questionnaires regarding relatives diagnosed with cancer.
According to these questionnaires, 31 individuals
reported additional breast or ovarian cancer cases in their
family. These patients were removed from the early-onset
group and were classified as familial cases. After taking
into account cancer incidences in relatives of patients
classified in the early-onset breast cancer group, 64 indi-
viduals remained.
2. The familial cases included in this study were indi-
viduals who had breast or ovarian cancer and at least one
relative diagnosed with these cancers. Familial cases were
identified at the Institute of Experimental and Clinical
Medicine (present name National Institute for Health
Development) and the Hematology and Oncology Clinic
of Tartu University Hospital. Pedigrees were drawn
according to information provided by the proband, and
cancer diagnoses were confirmed in the Estonian Cancer
Registry. Twenty-eight pedigrees encompassing 49 indi-
viduals blood samples and questionnaire were collected.
Among these individuals, 17 had cancer (14 breast, 2
ovarian, and 1 cervical cancer), and the rest were high-
risk relatives who were analyzed for predictive testing.
Familial cases consisted of 16 patients with breast or
ovarian cancer, who were analyzed for mutations in the
BRCA1 and BRCA2 genes. Additional 31 patients diag-
nosed with early onset breast cancer who were found to
have relatives with breast or ovarian cancer were also cat-
egorized as familial cases, and we analyzed the BRCA1
gene for mutations. In all, there were 47 familial cases.
3. Predictive testing cases included individuals from
high risk families (with two or more relatives diagnosed
with breast or ovarian cancer) who did not have breast or
ovarian cancer themselves. This group consisted of 33
individuals.
Blood samples were collected at two oncology centers:
the North Estonia Medical Centre's Centre of Oncology,
and the Hematology and Oncology Clinic of Tartu Uni-
versity Hospital.
All individuals who participated signed informed con-
sent forms. The study was approved by the Tallinn Medi-
cal Ethics Committee.
Mutation screening
To detect BRCA1 and BRCA2 mutations, we used SSCP-
HA followed by direct DNA sequencing. Genomic DNA
was isolated from blood samples using a DNA Isolation
Kit (Gentra Systems, Cat.no. GEND5500 or Fermentas
UAB Cat. No. K0512). The Polymerase Chain Reaction
(PCR) was used to amplify the entire coding sequence
and splice junctions of the BRCA1 and BRCA2 genes.
I n t r o n i c  p r i m e r s ,  d e s i g n e d  b y  S .  G a y t h e r ,  w e r e  t a k e n
from the BIC Primer Database http://
research.nhgri.nih.gov/projects/bic/ and used with minor
modifications. The PCR reaction mixture contained PCR
buffer, 1.5-3 mM MgCl2, 0.2 mM dNTPs, 10 pmol each
primer, 2 U Taq  DNA Polymerase, and 50-100 ng tem-
plate DNA. The PCR program consisted of one cycle at
95°C for 1 min, followed by 28-35 cycles of: 95°C for 20
sec; 47-62°C (depending on the primers) for 30 sec; and
72°C for 1 min. For mutation screening, we used SSCP-
HA. S. Gayther and B. Ponder describe the method in the
BIC Methods Database http://research.nhgri.nih.gov/
projects/bic/. SSCP and HA each have independent sen-
sitivities between 60% and 80%. The use of these two
techniques in combination (SSCP-HA) increases the
overall sensitivity, because both analyses are performed
on the same gel. We also used MDE (Mutation Detection
Enhancement) gels for SSCP-HA analysis. MDE is aTamboom et al. Hereditary Cancer in Clinical Practice 2010, 8:4
http://www.hccpjournal.com/content/8/1/4
Page 3 of 7
highly sensitive, high-resolution gel matrix specially for-
mulated to separate DNA based on both size and confor-
mation. This enables the detection of more mutations by
SSCP-HA analysis than would be possible using standard
polyacrylamide gels. The 0.6 × MDE (Cambrex, Cat.N.
50620) gels were analyzed by electrophoresis at 150-200V
in TBE buffer. Electrophoresis was performed under two
different conditions: one at 12°C and the other at 22°C.
The DNA Silver Staining Kit (Amersham Pharmacia Bio-
tech.Cat.N. 17-6000-30 or the method of Allen et al. [7])
was used for staining the gels. Fragments with aberrant
mobility detected on SSCP-HA gels were sequenced with
the BigDye Terminator cycle sequencing kit v3.1 (Applied
Biosystems). DNA sequencing reactions were carried out
on either ABI377 (Perkin Elmer) or ALF Express (Amer-
sham Pharmacia Biotech.Cat.N. 56-1173-21) instru-
ments. Both DNA strands were sequenced. All mutations
were confirmed by repeat PCR and sequencing.
Results
Thirteen sequence alterations were detected in the
BRCA1 gene (Table 1), three of which were considered
clinically significant, according to the BIC database:
c.3881_3882delGA, c.4154delA, and c.5382insC. One of
these, c.3881_3882delGA, was a novel mutation. The
m o s t  f r e q u e n t  m u t a t i o n  i n  t h e  B R C A 1  g e n e  w a s
c.5382insC, of which seven cases were found. The
c.4154delA mutation was detected in three cases. We also
observed the following six polymorphisms: c.2430T>C,
c.3232A>G, c.4158A>G, c.4427T>C, c.4956A>G and
c.5002T>C. Four sequence rearrangements were
detected in introns: c.560+64delT, c.560+ [36_38delCTT;
52_63del12], c.666-58delT, and
c.5396+60insGTATTCCACTCC.
Four sequence alterations were identified in the BRCA2
gene (T able 1). T wo of them were considered clinically
important: c.9610C>T is considered relevant according
to the BIC database, and c.6631delTTAAATG results in a
stop in codon 2167. Two mutations of unknown clinical
significance, c.7049G>T and c.7069+80delTTAG, were
also observed.
A cohort of 95 women with early-onset breast cancer,
diagnosed before age 45, was established and carefully
analyzed for mutations in the BRCA1 gene. The average
age of patients was 38 years, with the youngest patient
being 24 years old. Early-onset breast cancer patients
were also sub-grouped according to the incidence of can-
cer in relatives; patients who had at least one family
member with breast or ovarian cancer, in addition to an
early-onset diagnosis, were assigned as familial cases. Of
the 95 patients, 31 had additional breast or ovarian can-
cer in the family and 64 patients without a familial history
of these cancers were classified as early-onset cases. From
these 64 early-onset patients, 4 (6.3%) carried the clini-
cally important mutation c.5382insC in the BRCA1 gene.
Twenty three early-onset patients had a mutation with
unknown or no clinical significance in the BRCA1 gene
(Table 1).
The 16 familial case patients who had breast or ovarian
cancer and at least one relative with these cancers were
analyzed for mutations in the BRCA1 and BRCA2 genes.
In addition, 31 patients with early onset breast cancer and
a family history of breast or ovarian cancer were analyzed
for mutations in BRCA1. This group of familial cases
contained a total of 47 patients. Among familial cases,
mutations in the BRCA1 gene were observed in 6 patients
among 47 individuals analyzed (12.8%). Taken together,
these data indicate that the frequency of clinically impor-
tant BRCA1 mutations in early-onset and familial cases
in Estonia is 9% (10 mutations in 111 patients). With
regard to the BRCA2 gene, only some familial cases (16
cases) and all predictive cases were analyzed, and 2 indi-
viduals from the familial group had clinically important
mutations (12.5%). In predictive cases (N = 33), only one
clinically important mutation was detected in the BRCA1
gene.
Estonia has a population of only 1.35 million people,
and families tend to be quite small, with an average of 1.6
children per woman. Despite its small size, Estonia's pop-
ulation consists of several ethnic groups, the most com-
mon of which is Estonian (930,219), followed by Russian
(351,178), Ukrainian (29,021) and Belorussian (17,241)
[Statistics Estonia http://www.stat.ee/population-census-
2000]. This distribution was reflected in the composition
of our study participants. Our original early-onset breast
cancer patient group consisted of 49 Estonians, 41 Rus-
sians, 2 Ukrainians, 2 Belorussians and 1 Latvian. Muta-
tions were observed accordingly: 17 among Estonians, 19
in Russians, and 1 among both Ukrainians and Belorus-
sians. In familial cases, nationality was not documented.
Clinically important mutations in the BRCA1 gene
Three clinically important BRCA1 mutations were identi-
fied (Table 1 and 2). The c.5382insC mutation was the
most frequent (63.6% of mutations), and was observed in
four early-onset patients, two familial case patients, and
one predictive case. The c.4154delA mutation is the sec-
ond most frequent mutation, accounting for 27% of all
m u t a t i o n s ;  i t  w a s  f o u n d  i n  t h r e e  f a m i l i a l  c a s e s .  W e
detected the mutation c.3881_3882delGA in one familial
case (9% of mutations).
Sequence variations in the BRCA1 gene
Several sequence variations, which were not considered
clinically important, were also observed. Six of these were
detected in introns: the c.2430T>C variant (3 early-onset
cases, 6 familial cases, and one predictive case), the
c.3232A>G variant (4 early-onset cases), the c.4158A>GTamboom et al. Hereditary Cancer in Clinical Practice 2010, 8:4
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variant (3 predictive cases), the c.4427T>C variant (1
early-onset case), the c.4956A>G variant (5 early-onset
cases and 2 familial cases), and the c.5002T>C variant (1
early-onset case) (Table 1). Four sequence alterations
were detected in introns: c.560+64delT, c.560+
[36_38delCTT; 52_63del12], c.666-58delT, and
c.5396+60insGTATTCCACTCC. The c.560+64delT and
c.666-58delT alterations were both detected in 2 patients:
one with early-onset breast cancer and one with familial
cancer. The variant c.560+ [36_38delCTT; 52_63del12]
was found in 7 patients, 6 with early-onset breast cancer
and 1 with familial cancer. None of these mutations are
described in the BIC database. Finally, c.5396+60ins
GTATTCCACTCC was detected in one patient with
early-onset breast cancer. This mutation is described in
the BIC database, but is considered to be a mutation of
unknown clinical importance.
Mutations in the BRCA2 gene
In familial cases, we found two clinically important muta-
tions: c.6631delTTAAATG and c.9610C>T. The
c.6631delTTAAATG mutation was detected in one indi-
vidual, and is a novel mutation according to the BIC data-
base. The 6910C>T mutation was detected in one
individual. We also found two alterations with unknown
clinical significance: c.7049G>T in two individuals with
familial cancer, and c.7069+80delTTAG in three patients
with familial cancer and four predictive cases.
Incidence of cancer in relatives of BRCA1 and BRCA2 
mutation carriers
We next analyzed the incidence of cancer in relatives of
those individuals identified as carrying BRCA1or BRCA2
mutations. The cancer incidence in relatives is divided
into two groups 1) breast or ovarian, and 2) other cancer
types (Table 2). In the BRCA1 gene, four c.5382insC
mutation carriers were found in early-onset cases: 3 of
them did not have a family history of cancer, one patient's
grandfathers had gastric cancer, uncle had colorectal can-
cer, nieces had melanoma and uterus cancer. Two
c.5382insC mutation carriers were found in familial
cases: one patient's mother had breast cancer and grand-
mother had gastric cancer, and uncle had lung cancer,
and another patient's mother had ovarian cancer. One
c.5382insC mutation carrier was observed among the
predictive cases, three cases of breast cancer occurred in
Table 1: Mutations, polymorphisms, synonymous substitutions, and alterations in introns in the BRCA1 and BRCA 2 genes 
from an Estonian population.
Mutation Exon/
intron
Type of 
mutation
Effect on 
amino acids
Early-onset 
N = 64
Familia
l N = 47
Predictive 
N = 33
Clinical 
importance in 
BIC
BRCA1 Gene
c.560+64delT 7 intron deletion 1 1 0 new
c.560+ [36_38delCTT; 
52_63delCTTTTTTTTTTT]
7 intron deletion 6 1 0 new
c.666-58delT 8 intron deletion 1 1 0 new
c.2430T>C 11 exon synonymous Leu771Leu 3 6 1 no
c.3232A>G 11 exon missense Glu1038Gly 4 0 0 no
c.3881-3882delGA 11 exon frameshift stop 1265 0 1 0 yes
c.4154delA 11 exon frameshift stop 1365 0 3 0 yes
c.4158A>G 11 exon missense Arg1347Gly 0 0 3 unknown
c.4427T>C 13 exon synonymous Ser1436Ser 1 0 0 unknown
c.4956 A>G 16 exon missense Ser1613Gly 5 2 0 no
c.5002T>C 16 exon missense Met1628Thr 1 0 0 unknown
c.5382insC 20 exon frameshift stop 1829 4 2 1 yes
c.5396+60insGTATTCCACTCC 20 intron duplication 1 0 0 unknown
BRCA2 Gene
c.6631delTTAAATG 11 exon deletion Stop2167 0 1 0 new
c.9610C>T 25 exon nonsense Stop 3128 0 1 0 yes
c.7049G>T 11 exon missense Gly2274Val 0 2 0 unknown
c.7069+80delTTAG 11 intron deletion 0 3 4 unknownTamboom et al. Hereditary Cancer in Clinical Practice 2010, 8:4
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this family: two sisters and one aunt. Three c.4154delA
mutation carriers were found among familial cases: one
patient's grandmother had ovarian cancer, the second
patient's mother had breast cancer, and the third family
there was an additional case of ovarian cancer. One
patient was a c.3881-3882delGA mutation carrier: her
mother, sister, and aunt all had breast cancer, and her
uncle had larynx cancer.
Among mutations in the BRCA2 gene, one
c.6631delTTAAATG mutation carrier had a sister with
breast cancer, her aunt had ovarian cancer, and in addi-
tion, her brother had prostate cancer and her uncle had
gastric cancer. One individual with the 6910C>T muta-
tion had three cases of breast cancer in her family: in her
mother, sister and niece (Table 2).
Discussion
The relatively small population and family size in Estonia
is one reason families with at least two familial cases of
breast or ovarian cancer were included. This is also the
main reason we observed BRCA1 mutations in 12.8% and
BRCA2 mutations in 12.5% of the individuals who were
selected on the basis of family history. In early-onset
breast cancer, pathogenic mutations in BRCA1 were
found in 4 cases of 64 patients analyzed (6.3%). That falls
within the range reported in other studies. For example,
in a population-based study from France, the authors
analyzed patients that had been diagnosed with breast
cancer before age 46, and found deleterious mutations in
6.5% [8]. According to a population-based study from
Sweden, 6.8% of breast cancer patients younger than 41
carry mutations in the BRCA1 gene [9]. The BRCA1
mutation carrier frequency in young breast cancer
patients is lower in Estonia than in either Latvia or Rus-
sia, which lie just across its border. In Latvia, 26% of
young breast cancer patients (diagnosed before age 48)
were found to carry mutations in BRCA1 [10]. In a Rus-
sian study, breast cancer cases were selected according to
the presence of clinical indicators of hereditary disease,
such as bilaterality, onset by age 40, or family history, and
breast-cancer-associated alleles were detected in 15.2% of
subjects [11].
Table 2: Clinically important mutations in BRCA1 and BRCA2 genes and cancer incidence in relatives from Estonia.
Mutation Patient ID Nationality Age of cancer 
diagnosis
Breast or ovarian 
cancer in 
relatives
Other cancers in 
relatives
BRCA1 Gene
c.3881_3882del
GA
fam. 72 Russian 44: BrCa M:BrCa S:BrCa 
AU:BrCa
UN:LaCa
c.4154delA fam. 37 Russian 40: BrCa GM:OvCa no
c.4154delA fam. 13 Estonian 37: BrCa M:BrCa no
c.4154delA fam. 14/A079 Russian 48: OvCa M:OvCa no
c.5382insC early.40 Estonian 36: BrCa no no
c.5382insC early. 49 Russian 39: BrCa no no
c.5382insC early. 59 Russian 30: BrCa no GF1, GF2:GaCa, 
NI1:UtCa, 
UN:CoCa, NI2: Mel
c.5382insC fam. 62 Russian 43: BrCa M:BrCa GM:GaCa, 
UN:LuCa
c.5382insC early. 66 Russian 35: BrCa no no
c.5382insC fam. 77 Russian 38: BrCa M:OvCa no
c.5382insC pred. 49/A062 unknown ND S:BrCa, S:BrCa, 
AU:BrCa
no
BRCA2 Gene
c.6631delTTAAA
TG
fam. 16/A106 unknown 65: OvCa S: BrCa, AU:OvCa UN:GaCa, B:PrCa,
c.9610C>T fam. 03/A065 unknown 36: BrCa M:BrCa, S:BrCa, 
NI:BrCa
no
Abbreviations:
fam. Familial cases, early. Early-onset case, pred. Predictive case, ND not diagnosed (predictive testing). M mother, S sister, B brother, GM 
grandmother, GF grandfather, AU aunt, UN uncle, NI niece. BrCa breast cancer, OvCa ovary cancer, LaCa larynx cancer, GaCa gastric cancer, 
UtCa uterus cancer, CoCa colon cancer, Mel melanoma, LuCa lung cancer, PrCa prostate.Tamboom et al. Hereditary Cancer in Clinical Practice 2010, 8:4
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Clinically important mutations in the BRCA1 gene
The most frequent BRCA1 mutation in Estonia is
c.5382insC (63.6% of mutations). This mutation is highly
prevalent among the Ashkenazi Jewish population and
even more so in Eastern Europe. The c.5382insC muta-
tion is thought to have originated in the Baltic region
[[12] and [13]]. The frequency of this mutation is high in
Central and Eastern Europe: Russia (94% - 96%) [[14] and
[11]], Latvia (60%) [10] and Poland (51%) [15]. The
c.5382insC mutation is also found in Finland [16]. The
results from Estonia also support the theory regarding
the origin of the c.5382insC mutation.
T h e  s e c o n d  m o s t  f r e q u e n t  m u t a t i o n  i n  E s t o n i a  i s
c.4154delA (27% of mutations). This mutation is consid-
ered to be a specific mutation for Central and Eastern
Europe [17].
In Latvia, which neighbors Estonia, the two most prev-
alent mutations, c.4154delA and c.5382insC, represent
80% of all BRCA1 mutations [10]. In Estonia, these muta-
tions are also the most common c.5382insC (63.6%) and
4154delA (27%). The c.4154delA mutation is also preva-
lent in Finland [16].
The c.3881_3882delGA mutation was named according
to nomenclature for the description of sequence varia-
tions [Human Genome Variation Society http://
www.hgvs.org/mutnomen]. The same mutation with a
different name, c.3880delAG, has been described in one
breast cancer patient from Italy [18]. It appears in the
Breast Cancer Information Core database once, and can
be considered a rare mutation. This nonsense mutation
generates a premature stop codon at codon 1265, and so
c.3881_3882delGA can therefore be considered clinically
important.
Sequence alterations in the BRCA1 gene
The alterations in BRCA1 are considered not to be clini-
cally important according to the BIC database and infor-
mation in literature. Durocher and colleagues studied the
allelic variants c.2430T>C, c.3232A>G, c.4427T>C, and
c.4956A>G, and found no statistically significant differ-
ence in allele frequency between breast and ovarian can-
cer patients compared to a control population [19].
Deffenbaugh and colleagues found that the variant
c.4158A>G occurs at a heterozygote frequency of 2%. The
corresponding R1347 is not conserved in the murine
BRCA1 protein, and does not lie within the functional
domains of BRCA1. For these reasons, they interpreted
the c.4158A>G as a polymorphism being of no substan-
tial clinical significance [20]. Phelan and his group noted
that if an unknown variant co-occurs with a known dele-
terious mutation, it is unlikely to confer high risk itself.
An example of this is c.5002T>C (M1628T). In addition, a
functional assay of the M1628T variant showed tran-
scriptional activation similar to or greater than the wild
type BRCA1. Together, these data suggest that c.5002T>C
is not clinically significant [21].
Mutations in the BRCA2 gene
Among familial cases, we found two clinically important
mutations: c.6631delTTAAATG and c.9610C>T. The
c.6631delTTAAATG mutation is new according to the
BIC database. It is considered to be clinically important
because the mutation results in a stop codon at codon
2167.
Conclusions
We analyzed DNA from a total of 144 individuals from
Estonia: 64 women with early-onset breast cancer diag-
nosed before the age of 45, and 47 familial cases consist-
ing of patients with breast or ovarian cancer and at least
one family member diagnosed with these cancers, and 33
predictive cases, individuals without breast or ovarian
cancer, but having at least two cases of these cancers in
the family; performing a screen for mutations in the
BRCA1 gene. A sub-set of familial cases (N = 16) and all
predictive cases were additionally analyzed for mutations
in the BRCA2 gene. We used SSCP-HA followed by DNA
sequencing. Pathogenic mutations were identified in 4 of
the 64 early-onset breast cancer cases (6.3%). In familial
cases, clinically important mutations in the BRCA1 gene
were found in 6 of the 47 individuals analyzed (12.8%). In
predictive cases, 1 clinically important mutation was
detected in 33 individuals studied (3%). The occurrence
of clinically important mutations in BRCA2 in familial
cases of breast cancer was 2 of the 16 individuals ana-
lyzed (12.5%). We identified three clinically important
mutations in the BRCA1 gene in the cohort. The most
frequent mutation was c.5382insC (63.6%), the second
most frequent was c.4154delA (27%), and we identified
one individual with the c.3881_3882delGA mutation
(9%). We also observed several common polymorphisms
in addition to three new and one known sequence altera-
tion in introns. In familial cases, we identified two clini-
cally important mutations in the BRCA2 gene,
c.6631delTTAAATG and c.9610C>T (both in one case),
and two mutations of unknown clinical significance:
c.7049G>T and c.7069+80delTTAG. The mutation pat-
tern of BRCA1 from Estonia is characteristic for Eastern
and Central Europe.
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